

Petra Kovarkov

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2990049/petra-kovarikova-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

57
papers

1,093
citations

17
h-index

31
g-index

58
ext. papers

1,231
ext. citations

4.2
avg, IF

4.01
L-index

#	Paper	IF	Citations
57	Advanced microextraction techniques for the analysis of amphetamines in human breast milk and their comparison with conventional methods.. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021 , 210, 114549	3.5	1
56	The first chiral HPLC separation of dicarba-nido-undecaborate anions and their chromatographic behavior. <i>Talanta</i> , 2021 , 222, 121652	6.2	5
55	Electromembrane extraction of anthracyclines from plasma: Comparison with conventional extraction techniques. <i>Talanta</i> , 2021 , 223, 121748	6.2	7
54	Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase II inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity. <i>Scientific Reports</i> , 2021 , 11, 4456	4.9	1
53	Prodrug of ICRF-193 provides promising protective effects against chronic anthracycline cardiotoxicity in a rabbit model in vivo. <i>Clinical Science</i> , 2021 , 135, 1897-1914	6.5	1
52	The electromembrane extraction of pharmaceutical compounds from animal tissues. <i>Analytica Chimica Acta</i> , 2021 , 1177, 338742	6.6	4
51	Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation. <i>Circulation: Heart Failure</i> , 2021 , 14, e008209	7.6	2
50	Investigation of Structure-Activity Relationships of Dexrazoxane Analogs Reveals Topoisomerase II Interaction as a Prerequisite for Effective Protection against Anthracycline Cardiotoxicity. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020 , 373, 402-415	4.7	8
49	UHPLC-MS/MS method for analysis of sobuzoxane, its active form ICRF-154 and metabolite EDTA-diamide and its application to bioactivation study. <i>Scientific Reports</i> , 2019 , 9, 4524	4.9	1
48	Novel SPME fibers based on a plastic support for determination of plasma protein binding of thiosemicarbazone metal chelators: a case example of DpC, an anti-cancer drug that entered clinical trials. <i>Analytical and Bioanalytical Chemistry</i> , 2019 , 411, 2383-2394	4.4	4
47	Pharmacokinetics of the Cardioprotective Drug Dexrazoxane and Its Active Metabolite ADR-925 with Focus on Cardiomyocytes and the Heart. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018 , 364, 433-446	4.7	8
46	2,6-Dihydroxybenzaldehyde Analogues of the Iron Chelator Salicylaldehyde Isonicotinoyl Hydrazone: Increased Hydrolytic Stability and Cytoprotective Activity against Oxidative Stress. <i>Chemical Research in Toxicology</i> , 2018 , 31, 1151-1163	4	6
45	Structure-Activity Relationships of Nitro-Substituted Aroylhydrazone Iron Chelators with Antioxidant and Antiproliferative Activities. <i>Chemical Research in Toxicology</i> , 2018 , 31, 435-446	4	3
44	Investigation of novel dexrazoxane analogue JR-311 shows significant cardioprotective effects through topoisomerase IIbeta but not its iron chelating metabolite. <i>Toxicology</i> , 2017 , 392, 1-10	4.4	20
43	Are cardioprotective effects of NO-releasing drug molsidomine translatable to chronic anthracycline cardiotoxicity settings?. <i>Toxicology</i> , 2016 , 372, 52-63	4.4	1
42	Cardioprotective effects of iron chelator HAPI and ROS-activated boronate prochelator BHAPI against catecholamine-induced oxidative cellular injury. <i>Toxicology</i> , 2016 , 371, 17-28	4.4	11
41	A UHPLC-UV-QTOF study on the stability of carfilzomib, a novel proteasome inhibitor. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016 , 124, 365-373	3.5	9

40	Characterization of cytoprotective and toxic properties of iron chelator SIH, prochelator BSIH and their degradation products. <i>Toxicology</i> , 2016 , 350-352, 15-24	4.4	7
39	Zinc(II)-Thiosemicarbazone Complexes Are Localized to the Lysosomal Compartment Where They Transmetallate with Copper Ions to Induce Cytotoxicity. <i>Journal of Medicinal Chemistry</i> , 2016 , 59, 4965-84	8.3	114
38	Aroylhydrazone iron chelators: Tuning antioxidant and antiproliferative properties by hydrazide modifications. <i>European Journal of Medicinal Chemistry</i> , 2016 , 120, 97-110	6.8	23
37	Interface-free capillary electrophoresis-mass spectrometry system with nanospray ionization-Analysis of dexrazoxane in blood plasma. <i>Journal of Chromatography A</i> , 2016 , 1466, 173-9	4.5	13
36	LC-UV/MS methods for the analysis of prochelator-boronyl salicylaldehyde isonicotinoyl hydrazone (BSIH) and its active chelator salicylaldehyde isonicotinoyl hydrazone (SIH). <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015 , 105, 55-63	3.5	9
35	In Vitro Characterization of the Pharmacological Properties of the Anti-Cancer Chelator, Bp4eT, and Its Phase I Metabolites. <i>PLoS ONE</i> , 2015 , 10, e0139929	3.7	6
34	Novel and potent anti-tumor and anti-metastatic di-2-pyridylketone thiosemicarbazones demonstrate marked differences in pharmacology between the first and second generation lead agents. <i>Oncotarget</i> , 2015 , 6, 42411-28	3.3	23
33	Simultaneous determination of the novel thiosemicarbazone anti-cancer agent, Bp4eT, and its main phase I metabolites in plasma: application to a pilot pharmacokinetic study in rats. <i>Biomedical Chromatography</i> , 2014 , 28, 621-9	1.7	7
32	ANTHRACYCLINE CARDIOTOXICITY: THE PHARMACOKINETICS AND PHARMACODYNAMICS OF DEXRAZOXANE AND ITS OPEN RING METABOLITE. <i>Heart</i> , 2014 , 100, A7.1-A7	5.1	
31	Structure-activity relationships of novel salicylaldehyde isonicotinoyl hydrazone (SIH) analogs: iron chelation, anti-oxidant and cytotoxic properties. <i>PLoS ONE</i> , 2014 , 9, e112059	3.7	13
30	Zirconia--a stationary phase capable of the separation of polar markers of myocardial metabolism in hydrophilic interaction chromatography. <i>Journal of Separation Science</i> , 2014 , 37, 1089-93	3.4	4
29	Deferoxamine but not dexrazoxane alleviates liver injury induced by endotoxemia in rats. <i>Shock</i> , 2014 , 42, 372-9	3.4	15
28	Identification of in vitro metabolites of the novel anti-tumor thiosemicarbazone, DpC, using ultra-high performance liquid chromatography-quadrupole-time-of-flight mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2013 , 405, 1651-61	4.4	5
27	Development of LC-MS/MS method for the simultaneous analysis of the cardioprotective drug dexrazoxane and its metabolite ADR-925 in isolated cardiomyocytes and cell culture medium. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2013 , 76, 243-51	3.5	9
26	Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection. <i>Antioxidants and Redox Signaling</i> , 2013 , 18, 899-929	8.4	219
25	LC-MS/MS identification of the principal in vitro and in vivo phase I metabolites of the novel thiosemicarbazone anti-cancer drug, Bp4eT. <i>Analytical and Bioanalytical Chemistry</i> , 2012 , 403, 309-21	4.4	13
24	Methyl and ethyl ketone analogs of salicylaldehyde isonicotinoyl hydrazone: novel iron chelators with selective antiproliferative action. <i>Chemico-Biological Interactions</i> , 2012 , 197, 69-79	5	34
23	Comparison of various iron chelators used in clinical practice as protecting agents against catecholamine-induced oxidative injury and cardiotoxicity. <i>Toxicology</i> , 2011 , 289, 122-31	4.4	28

22	Iron chelation with salicylaldehyde isonicotinoyl hydrazone protects against catecholamine autoxidation and cardiotoxicity. <i>Free Radical Biology and Medicine</i> , 2011 , 50, 537-49	7.8	38
21	The retention behaviour of polar compounds on zirconia based stationary phases under hydrophilic interaction liquid chromatography conditions. <i>Journal of Chromatography A</i> , 2011 , 1218, 6981-6	4.5	23
20	Synthesis and initial in vitro evaluations of novel antioxidant aroylhydrazone iron chelators with increased stability against plasma hydrolysis. <i>Chemical Research in Toxicology</i> , 2011 , 24, 290-302	4	48
19	Enhanced topical and transdermal delivery of antineoplastic and antiviral acyclic nucleoside phosphonate cPr-PMEDAP. <i>Pharmaceutical Research</i> , 2011 , 28, 3105-15	4.5	10
18	Use of different stationary phases for separation of isoniazid, its metabolites and vitamin B6 forms. <i>Journal of Separation Science</i> , 2011 , 34, 1357-65	3.4	12
17	Hydrophilic interaction liquid chromatography in the separation of a moderately lipophilic drug from its highly polar metabolites—the cardioprotectant dexrazoxane as a model case. <i>Journal of Chromatography A</i> , 2011 , 1218, 416-26	4.5	16
16	Comparison of clinically used and experimental iron chelators for protection against oxidative stress-induced cellular injury. <i>Chemical Research in Toxicology</i> , 2010 , 23, 1105-14	4	53
15	Development of an LC-MS/MS method for analysis of interconvertible Z/E isomers of the novel anticancer agent, Bp4eT. <i>Analytical and Bioanalytical Chemistry</i> , 2010 , 397, 161-171	4.4	8
14	Dimethylamino acid esters as biodegradable and reversible transdermal permeation enhancers: effects of linking chain length, chirality and polyfluorination. <i>Pharmaceutical Research</i> , 2009 , 26, 811-21	4.5	27
13	Development and Validation of an LCESI-MS Ion-Trap Method for Analysis of Impurities in Transkarbam 12, a Novel Transdermal Accelerant. <i>Chromatographia</i> , 2009 , 69, 977-983	2.1	1
12	HPLC methods for determination of two novel thiosemicarbazone anti-cancer drugs (N4mT and Dp44mT) in plasma and their application to in vitro plasma stability of these agents. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009 , 877, 316-22	3.2	18
11	HPLC-DAD and MS/MS analysis of novel drug candidates from the group of aromatic hydrazones revealing the presence of geometric isomers. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2008 , 48, 295-302	3.5	21
10	Determination of lipophilicity of novel potential antituberculosic agents using HPLC on monolithic stationary phase and theoretical calculations. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2008 , 48, 310-4	3.5	14
9	Investigation of the stability of aromatic hydrazones in plasma and related biological material. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2008 , 47, 360-70	3.5	30
8	Development and validation of HPLC-DAD methods for the analysis of two novel iron chelators with potent anti-cancer activity. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2007 , 43, 1343-51	3.5	11
7	HPLC study on stability of pyridoxal isonicotinoyl hydrazone. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2006 , 40, 105-12	3.5	17
6	HPLC determination of a novel aroylhydrazone iron chelator (o-108) in rabbit plasma and its application to a pilot pharmacokinetic study. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2006 , 838, 107-12	3.2	14
5	Determination of the lipophilicity of potential antituberculosic compounds by RP-TLC. <i>Journal of Planar Chromatography - Modern TLC</i> , 2006 , 19, 422-426	0.9	10

- | | | | |
|---|--|-----|----|
| 4 | Development of high-performance liquid chromatographic determination of salicylaldehyde isonicotinoyl hydrazone in rabbit plasma and application of this method to an in vivo study. <i>Journal of Separation Science</i> , 2005 , 28, 1300-6 | 3-4 | 30 |
| 3 | Chromatographic methods for the separation of biocompatible iron chelators from their synthetic precursors and iron chelates. <i>Journal of Separation Science</i> , 2004 , 27, 1503-10 | 3-4 | 11 |
| 2 | HPLC study of glimepiride under hydrolytic stress conditions. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2004 , 36, 205-9 | 3-5 | 32 |
| 1 | Photochemical stability of nimesulide. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2003 , 31, 827-32 | 3-5 | 15 |